| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 1
| Issue : 2 | Page : 120-123 |
|
|
Chronic myeloid leukemia and ferritin levels
Kumar Saurabh, Veena Singh Ghalaut, Jyoti Bala
Department of Biochemistry, Pt. B.D. Sharma PGIMS, Rohtak, Haryana, India
Correspondence Address:
Jyoti Bala
D-2, New Bharat Nagar, Bhiwani, Haryana
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/bbrj.bbrj_64_17
|
|
|
Background: Ferritin is a positive acute-phase reactant, exhibiting increased levels in blood during the acute-phase response. High plasma ferritin levels have been reported for various types of cancers, irrespective of the amount of total body iron. Hence, this study was designed to assess the status of ferritin levels in chronic myeloid leukemia (CML) patients both before and after chemotherapy and to compare them with age- and sex-matched healthy controls. Methods: Thirty patients of CML after confirmed diagnosis were taken up for the study. CML patients were treated by imatinib therapy. Serum ferritin was estimated by enzyme-linked immunosorbent assay in thirty newly diagnosed CML patients and in thirty age- and sex-matched healthy controls. The test was repeated at first complete remission or at 3 months (whichever is earlier) in CML patients. Patients and controls were categorized into three groups as follows: (1) Group I: Control group –age- and sex-matched healthy volunteers (2) Group II: CML patients at the time of diagnosis (before imatinib therapy) (3) Group III: CML patients at first complete remission or at 3 months of imatinib therapy (whichever is earlier). Results: The ferritin levels were significantly increased in Group II and Group III (387.68 ± 221.61 ng/mL and 295.43 ± 169.17 ng/mL, respectively) as compared to controls (73.27 ± 60.82 ng/mL) (P = 0.000 and P = 0.000, respectively). The ferritin levels were decreased in Group III as compared to Group II, although the difference was not statistically significant (P = 0.075). Conclusion: Our study revealed that serum ferritin could be a useful marker in determining disease progression or monitor the effectiveness of treatment in leukemic patients.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
